RPV/FTC/TAF rilpivirine/emtricitabine/tenofovir alafenamide

Recommended initial regimen in certain clinical situations
Single-Tablet Regimen

Standard Dose

One tablet once daily, with a standard meal (more than 390 calories). For people taking HIV therapy for the first time (treatment-naïve) or people with suppressed viral load on a stable HIV regimen for at least 6 months who have no known resistance to the rilpivirine, emtricitabine, or tenofovir components of the regimen. See below. Tablet contains 25 mg of the NNRTI rilpivirine plus 200 mg emtricitabine and 25 mg tenofovir alafenamide (TAF).

Must be taken with a meal that you chew—not just nutritional drinks or protein shakes. Taking rilpivirine without food could result in a 40% decrease in drug absorption and may lead to resistance.

People taking HIV treatment for the first time must have an HIV RNA (viral load) of less than 100,000 copies/mL and a CD4 T cell count of more than 200 cells/mm3 before starting Odefsey due to higher rates of virologic failure in these patients.

For adults and children 12 years of age and older weighing at least 77 pounds (35 kg) and having a CrCl of at least 30 mL/min, or people with a CrCl less than 15 mL/min who are receiving dialysis.

Take missed dose as soon as possible, unless it is closer to the time of your next dose. Do not double up on your next dose

See the individual drugs contained in Odefsey: Edurant and Descovy (co-formulation of Emtriva and TAF).

See package insert for more complete information on potential side effects and interactions.


Gilead Sciences, Inc.
(800) GILEAD-5 (445-3235)

Janssen Therapeutics
(800) JANSSEN (526-7736)



Potential Side Effects and Toxicity

Potential Drug Interactions

More Information

Doctor Comments

Activist Comments